The call ran from 6:01 PM to 6:32 PM IST (31 min).
Key takeaways
Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.
| Revenue growth | Revenue ~₹477 Cr, +13% QoQ; YoY lower, unquantified. |
|---|---|
| Margins | Adj EBITDA margin ~10%, up QoQ; lower YoY. |
| Order book | Q3-Q4 reload visibility improved; three new programs won. |
| Demand visibility | Reload orders improved for Q3-Q4; ADC destocking hurt payload demand. |
| Management confidence | Balanced; H2 recovery confident but unquantified. |
Growth
Revenue up ~13% QoQ, but YoY lower: Pharma CDMO -27%, API Plus +5%, Oligo +33.6%. Specialty chemicals -40.6% YoY.
Outlook
H2 FY27 YoY revenue and EBITDA growth expected, with no figures given. Specialty chemicals FY27 revenue guided to decline YoY.
Risks
Specialty chemicals now guided to decline in FY27. ADC customer destocking, USFDA remediation, and unassessed Surya Pake closure impact.
Last quarter's promises, checked
Delivered
- Seq Q2 rev growth → ₹477 Cr vs ₹422 Cr (+13% QoQ) (= BEAT)
- Seq EBITDA recovery → ~₹46 Cr vs ₹9.2 Cr (= BEAT)
Partly delivered
- Q2 Pharma CDMO 'significantly better' → YoY -38.7% narrowed to -27% (= PARTIAL)
- ADC payload on schedule Q2FY27 → destocking hurt demand; delivery unconfirmed (= PARTIAL)
Missed
- YoY comparability by end-H1 → still YoY lower; Spec Chem -40.6% (= MISS)
- FY27 margin near prior-year → ~10% adj, lower YoY (= MISS)
- FY27 Spec Chem H2-skewed growth → FY27 guided decline (= MISS)
Summary by ALFA Finder, written with AI assistance from our own recording of the call, published . Open it on ALFA Filings ›
The results behind this call
Cohance Lifesciences Q2 FY27 Results: Net Profit ₹2.3 Cr, Down 96.5% YoY
Cohance Lifesciences Ltd reported revenue from operations of ₹476.6 Cr (-14.2% YoY) and net profit of ₹2.3 Cr (-96.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹2.3 Cr · -96.5% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Management expects sequential improvement in Q2 and a return to YoY growth starting in H2 FY27.
Growth they described
Pharma CDMO revenue plunged 38.7% YoY due to destocking, partially offset by 2.5x growth in the Sapala subsidiary.
Call details
| Company | Cohance Lifesciences Limited |
|---|---|
| NSE symbol | COHANCE |
| ISIN | INE03QK01018 |
| Call | Q2 FY27 earnings call |
| Date | Friday, 6 November 2026 |
| Time | 6:00 PM IST |
| Length | 31 min |
| Audio | Our stream on YouTube ↗ |
Cohance Lifesciences Limited: key numbers
- Share price
- ₹433.00
- Market cap
- ₹16,566 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 155.9×Sector 42.0×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Fri, 6 Nov
Today's concalls →
